Ginkgo BioworksDNA
DNA
About: Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Employees: 834
0
Funds holding %
of 7,316 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
59% more call options, than puts
Call options by funds: $5.98M | Put options by funds: $3.76M
58% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 31
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
1% more funds holding
Funds holding: 165 [Q4 2024] → 166 (+1) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
0.17% less ownership
Funds ownership: 71.91% [Q4 2024] → 71.74% (-0.17%) [Q1 2025]
42% less capital invested
Capital invested by funds: $319M [Q4 2024] → $184M (-$135M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for DNA.
Financial journalist opinion
Negative
Zacks Investment Research
4 days ago
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $10.79, denoting a -2.53% move from the preceding trading day.
Positive
Zacks Investment Research
2 weeks ago
Ginkgo Bioworks (DNA) Soars 18.9%: Is Further Upside Left in the Stock?
Ginkgo Bioworks (DNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
PRNewsWire
1 month ago
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
BOSTON , May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation.
Neutral
Business Wire
2 months ago
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Under the terms of the revised three-year $15 million agr.
Neutral
Seeking Alpha
2 months ago
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Mark Massaro - BTIG Tejas Savant - Morgan Stanley Evie Koslosky - Goldman Sachs Matt Larew - William Blair Brendan Smith - TD Cowen Operator [Call Starts Abruptly] live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
Negative
Zacks Investment Research
2 months ago
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago.
Neutral
PRNewsWire
2 months ago
Ginkgo Bioworks Reports First Quarter 2025 Financial Results
Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
Negative
Zacks Investment Research
2 months ago
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $7.37, representing a -0.14% change from its previous close.
Neutral
PRNewsWire
2 months ago
Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors
Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors.
Neutral
PRNewsWire
2 months ago
Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation
Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON , April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
Charts implemented using Lightweight Charts™